Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ariad investors retreat on FDA probe of Iclusig

This article was originally published in Scrip

Executive Summary

After taking a beating earlier in the week, shares of Ariad Pharmaceuticals were pounded again on 11 October, tumbling as low as 22%, after US regulators said they had opened a probe into the increase in reports of serious and life-threatening blood clots and severe narrowing of blood arteries and veins in patients taking the company's oral leukemia drug Iclusig (ponatinib), a kinase inhibitor.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC023081

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel